DAFTAR PUSTAKA

Abdalhamid, B., Albunayan, S., Shaikh, A., Elhadi, N., Aljindan, R. 2017. Prevalence study of plasmid-mediated AmpC β-lactamases in *Enterobacteriaceae* lacking inducible AmpC from Saudi hospitals. *J. Med. Microbiol.*, 66(9):1286–1290.

Ataee, R.A., Mehrabi, A., Hosseini, S., Moridi, K., Ghorbanalizadgan, M. 2012. A method for antibiotic ausceptibility testing: applicable and accurate. *Jundishapur J. Microbiol.*, 5:341–345.

Bala, R., Singh, V.A., Gupta, N., Rakshit, P. 2020. Prevalence, multidrug-resistance and risk factors for AmpC β-lactamases producing *Escherichia coli* from hospitalized patients. *J. Infect. Dev. Ctries.*, 14(12):1466–1469.

Bauer, A.W., Kirby, W.M., Sherris, J.C., Turck, M. 1966. Antibiotic susceptibility testing by a standardized single disk method. *Am. J. Clin. Pathol.*, 45(4):493–496.

Belkum, A. van, Burnham, C.A.D., Rossen, J.W.A., Mallard, F., Rochas, O., Dunne, W.M. 2020. Innovative and rapid antimicrobial susceptibility testing systems. *Nat. Rev. Microbiol. 2020 185*, 18(5):299–311.

Black, J.A., Moland, E.S., Thomson, K.S. 2005. AmpC disk test for detection of plasmid-mediated AmpC β-lactamases in *Enterobacteriaceae* lacking chromosomal AmpC β-lactamases. *J. Clin. Microbiol.*, 43(7):3110–3113.

Bobenchik, A.M., Deak, E., Hindler, J.A., Charlton, C.L., Humphries, R.M. 2017. Performance of Vitek 2 for antimicrobial susceptibility testing of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Stenotrophomonas maltophilia* with Vitek 2 (2009 FDA) and CLSI M100S 26th edition breakpoints. *J. Clin. Microbiol.*, 55(2):450–456.

Chart, H. 2012. *Klebsiella*, *Enterobacter*, *Proteus* and other *Enterobacteria*: Pneumonia; urinary tract infection; opportunist infection. *In:* Greenwood, D. et al., editors, *Med. Microbiol.* 18th ed. Edinburgh: Churchill Livingstone, 290–297.

Chavada, R., Tong, D., Maley, M. 2018. In-Hospital Surgery as a Risk Factor for Onset of AmpC-Producing *Escherichia coli* Blood Stream Infections. *Diseases*, 6(3):71.

Cižman, M., Srovin, T.P. 2018. Antibiotic consumption and resistance of gram-negative pathogens (collateral damage). *GMS Infect. Dis.*, 6:Doc05.

CLSI. 2021. *Performance standards for antimicrobial susceptibility testing, CLSI supplement M100*. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute.

Delgado-Valverde, M., Sojo-Dorado, J., Pascual, A., Rodríguez-Baño, J. 2013.

Clinical management of infections caused by multidrug-resistant *Enterobacteriaceae*. *Ther. Adv. Infect. Dis.*, 1(2):49–69.

Ding, H., Yang, Y., Lu, Q., Wang, Y., Chen, Y., Deng, L., Wang, A., Deng, Q., Zhang, H., Wang, C., Liu, L., Xu, X., Wang, L., Shen, X. 2008. The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from five children's hospitals in China. *Eur. J. Clin. Microbiol. Infect. Dis.*, 27(10):915–921.

Etemadi, S., Ebrahimzadeh Leylabadlo, H., Ghotaslou, R. 2020. AmpC β-lactamase among *Enterobacteriaceae*: a new insight. *Gene Reports*, 19(01):100673.

Gupta, G., Tak, V., Mathur, P. 2014. Detection of AmpC β Lactamases in Gram-negative Bacteria. *J. Lab. Physicians*, 6(01):001–006.

Hassan, A., Usman, J., Kaleem, F., Gill, M.M., Khalid, A., Iqbal, M., Ingram, P. 2013. Evaluation of different phenotypic methods for detection of AmpC beta-lactamase producing bacteria in clinical isolates. *J. Coll. Physicians Surg. Pak.*, 23(9):629–32.

Ibrahim, M.E., Abbas, M., Al-Shahrai, A.M., Elamin, B.K. 2019. Phenotypic characterization and antibiotic resistance patterns of extended-spectrum β -lactamase- and AmpC β -lactamase-producing Gram-negative bacteria in a referral hospital, Saudi Arabia. *Can. J. Infect. Dis. Med. Microbiol.*, 2019.

Ingram, P.R., Inglis, T.J.J., Vanzetti, T.R., Henderson, B.A., Harnett, G.B., Murray, R.J. 2011. Comparison of methods for AmpC β-lactamase detection in *Enterobacteriaceae*. *J. Med. Microbiol.*, 715–721.

Kementerian Kesehatan RI. 2015. Permenkes RI No. 8 Tahun 2015 tentang program pengendalian resistensi antimikroba di rumah sakit. *Hukor Depkes RI* [Preprint]. Jakarta: Kementerian Kesehatan Republlik Indonesia.

Lee, C.H., Lee, Y.T., Kung, C.H., Ku, W.W., Kuo, S.C., Chen, T.L., Fung, C.P. 2015. Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing *Enterobacteriaceae*. *J. Microbiol. Immunol. Infect.*, 48(3):269–275.

Li, Y.Y., Cassidy, F., Salmon, A., Keating, D., Herra, C.M., Schaffer, K. 2015. Detection and epidemiology of plasmid-mediated AmpC β-lactamase producing *Escherichia coli* in two Irish tertiary care hospitals. *J. Glob. Antimicrob. Resist.*, 3(4):242–246.

Lin, X., Kück, U. 2022. Cephalosporins as key lead generation beta-lactam antibiotics. *Appl. Microbiol. Biotechnol.*, 106(24):8007–8020.

Manchanda, V., Singh, N.P. 2003. Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. *J. Antimicrob. Chemother.*, 51(2):415–418.

Martin, R.M., Bachman, M.A. 2018. Colonization, infection, and the accessory genome of *Klebsiella pneumoniae*. *Front. Cell. Infect. Microbiol.*, 8(JAN):1–15.

Meini, S., Tascini, C., Cei, M., Sozio, E., Rossolini, G.M. 2019. AmpC β-lactamase-producing *Enterobacterales*: what a clinician should know. *Infection*, 47(3):363–375.

Mylvaganam, H., Kolstad, H., Breistein, R.I., Lind, G., Skutlaberg, D.H. 2017. Extended spectrum cephalosporin resistance among clinical isolates of *Enterobacteriaceae* in West Norway during 2006–2013; a prospective surveillance study. *APMIS*, 125(1):52–58.

Nakai, H., Hagihara, M., Kato, H., Hirai, J., Nishiyama, N., Koizumi, Y., Sakanashi, D., Suematsu, H., Yamagishi, Y., Mikamo, H. 2016. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae*. *J. Infect. Chemother.*, 22(5):319–326.

Nelson, G.E., Greene, M.H. 2020. Enterobacteriaceae. *In:* Bennet, J.E., Dolin, R., and Blaser, M.J., editors, *Mand. Douglas, Bennett's Princ. Pract. Infect. Dis.* 9th ed. Philadelphia, PA: Elsevier Ltd, 2669–2685. Available at: https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/book/3-s2.0-B9780323482554002186?scrollTo=%23hl0001608.

Ngurah, G., Priyaka, K., Made, N., Tarini, A., Nengah, N., Fatmawati, D., Klnik, M., Sanglah, R. 2019. Deteksi molekuler gen AmpC pada isolat klinis *Klebsiella pneumoniae* penghasil ESBL di RSUP Sanglah Denpasar. *E-Jurnal Med. Udayana*, 8(11):2597–8012.

Paczosa, M.K., Mecsas, J. 2016. *Klebsiella pneumoniae*: going on the offense with a strong defense. *Microbiol. Mol. Biol. Rev.*, 80(3):629–661.

Park, Y.S., Yoo, S., Seo, M.R., Kim, J.Y., Cho, Y.K., Pai, H. 2009. Risk factors and clinical features of infections caused by plasmid-mediated AmpC β-lactamase-producing *Enterobacteriaceae*. *Int. J. Antimicrob. Agents*, 34(1):38–43.

Park, Y.S., Adams-Haduch, J.M., Shutt, K.A., Yarabinec, D.M., Johnson, L.E., Hingwe, A., Lewis, J.S., Jorgensen, J.H., Doi, Y. 2012. Clinical and Microbiologic Characteristics of Cephalosporin-Resistant *Escherichia coli* at Three Centers in the United States.

Pascual, V., Ortiz, G., Simó, M., Alonso, N., Garcia, M.C., Xercavins, M., Rivera, A., Morera, M.A., Miró, E., Espejo, E., Navarro, F., Gurguí, M., Pérez, J., Rodríguez-Carballeira, M., Garau, J., Calbo, E. 2015. Epidemiology and risk factors for infections due to AmpC β-lactamase-producing *Escherichia coli*. *J. Antimicrob. Chemother.*, 70(3):899–904.

Patil, A.B., Medegar, S., Professor, A. 2020. Multivariate analysis of risk factors

for ESBL and AmpC producing *Escherichia coli* and *Klebsiella pneumoniae* at a Tertiary Care Hospital in Karnataka: A case control study. *Indian J. Microbiol. Res.*, 5(1):1–6.

PPRA RSUP Dr. Sardjito. 2021. *Laporan PPRA RSUP Dr. Sarjito Tahun 2021*. Yogyakarta: RSUP Dr. Sardjito.

Rand, K.H., Turner, B., Seifert, H., Hansen, C., Johnson, J.A., Zimmer, A. 2011. Clinical laboratory detection of AmpC β-lactamase: does it affect patient outcome? *Am. J. Clin. Pathol.*, 135(4):572–576.

Robatjazi, S., Nikkhahi, F., Niazadeh, M., Amin Marashi, S.M., Peymani, A., Javadi, A., Kashani, A.H. 2021. Phenotypic Identification and Genotypic Characterization of Plasmid-Mediated AmpC β-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates in Iran. *Curr. Microbiol.*, 78(6):2317–2323.

Rodríguez-Baño, J., Miró, E., Villar, M., Coelho, A., Gozalo, M., Borrell, N., Bou, G., Conejo, M.C., Pomar, V., Aracil, B., Larrosa, N., Agüero, J., Oliver, A., Fernández, A., Oteo, J., Pascual, A., Navarro, F. 2012. Colonisation and infection due to *Enterobacteriaceae* producing plasmid-mediated AmpC β-lactamases. *J. Infect.*, 64(2):176–183.

Singhal, S., Mathur, T., Khan, S., Upadhyay, D.J., Chugh, S., Gaind, R., Rattan, A. 2005. Evaluation of methods for AmpC β-lactamase in Gram negative clinical isolates from tertiary care hospitals. *Indian J. Med. Microbiol.*, 23(2):120–124.

Tang, W., Hu, J., Zhang, H., Wu, P., He, H. 2015. Kappa coefficient: a popular measure of rater agreement. *Shanghai Arch. Psychiatry*, 27(1):62.

Tekele, S.G., Teklu, D.S., Tullu, K.D., Birru, S.K., Legese, M.H. 2020. Extended-spectrum beta-lactamase and AmpC beta-lactamases producing gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. *PLoS One*. Edited by G. Wo?niakowski, 15(11):e0241984.

Tewari, R., Mitra, S.D., Ganaie, F., Venugopal, N., Das, S., Shome, R., Rehman, H., Shome, B.R. 2018. Prevalence of extended spectrum β-lactamase, AmpC β-lactamase and metallo β-lactamase mediated resistance in *Escherichia coli* from diagnostic and tertiary healthcare centers in South Bangalore, India. *Int. J. Res. Med. Sci.*, 6(4):1308.

Tsui, K., Wong, S.S., Lin, L.C., Tsai, C.R., Chen, L.C., Huang, C.H. 2012. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to *Escherichia coli* and *Klebsiella pneumoniae* Producing Extended-Spectrum and AmpC type β-Lactamases. *J. Microbiol. Immunol. Infect.*, 45(3):193–199.

World Health Organization, W. 2018. *DDD-Definition and general considerations*.

Available at: https://www.whocc.no/ddd/definition_and_general_considera/ (Accessed: 30 November 2022).

Wu, M., Li, X. 2015. *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. *In:* Tang, Y.-W. et al., editors, *Mol. Med. Microbiol.* 2nd Ed. Philadelphia, PA: Elsevier, 1547–1564.

Yilmaz, N.O., Agus, N., Bozcal, E., Oner, O., Uzel, A. 2013. Detection of plasmid-mediated AmpC β-lactamase in *Escherichia coli* and *Klebsiella pneumoniae*. *Indian J. Med. Microbiol.*, 31(1):53–59.

Zerr, D.M., Miles-Jay, A., Kronman, M.P., Zhou, C., Adler, A.L., Haaland, W., Weissman, S.J., Elward, A., Newland, J.G., Zaoutis, T., Qin, X. 2016. Previous antibiotic exposure increases risk of infection with extended-spectrum-β-lactamase- and AmpC-producing *Escherichia coli* and *Klebsiella pneumoniae* in pediatric patients. *Antimicrob. Agents Chemother.*, 60(7):4237–4243.

Zhang, Q., Zhang, W., Li, Z., Bai, C., Li, D., Zheng, S., Zhang, P., Zhang, S. 2017. Bacteraemia due to AmpC β-lactamase-producing *Escherichia coli* in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. *Diagn. Microbiol. Infect. Dis.*, 88(3):247–251.